FrancophonIA/ELRC3.0 huggingface dataset:
English: Cardboard box with 10 lyophilisate vials containing 1,000 doses.
Croatian: Kartonska kutija s 10 liofiliziranih bočica koje sadrže 1000 doza.
English: PARTICULARS TO APPEAR ON THE OUTER PACKAGE Cardboard boxes (solvent bags)
Croatian: Kartonske kutije (vrećice za otapalo)
English: Cardboard box with 10 lyophilisate vials containing 5,000 doses.
Croatian: Kartonska kutija s 10 liofiliziranih bočica koje sadrže 5000 doza.
English: Cardboard box with 10 lyophilisate vials containing 4,000 doses.
Croatian: Kartonska kutija s 10 liofiliziranih bočica koje sadrže 4000 doza.
English: Cardboard box with 10 lyophilisate vials containing 2,000 doses.
Croatian: Kartonska kutija s 10 liofiliziranih bočica koje sadrže 2000 doza.
English: la Selva, 135
Croatian: LABORATORIOS HIPRA, S.A. Avda. la Selva, 135
English: Hipra Italia S.r.l.
Croatian: HIPRA UK AND IRELAND, Ltd.
English: Avda.
Croatian: Tel.
English: Solvent:
Croatian: Liofilizat:
English: Dilutions for in ovo administration (0.05 ml per dose) Number and content of vaccine vials:
Croatian: Razrjeđenja za davanje in ovo (0,05 ml po dozi):
English: IBDV-specific antibody solution…………………………….. 2.7x106 VNU** of IgY per vial **VNU: Virus Neutralisation Units
Croatian: 2,7x106 VNU** of IgY po bočici
English: B. PACKAGE LEAFLET
Croatian: Bočica liofilizata
English: Marketing authorisation holder and manufacturer responsible for batch release: Laboratorios Hipra, S.A.
Croatian: Nositelj odobrenja za stavljanje u promet i proizvođač odgovoran za puštanje serije u promet:
English: IBDV-specific antibody solution………………………………2.7x106 VNU** of IgY per vial **VNU: Virus Neutralisation Units
Croatian: Pomoćne tvari: IBDV-specifična otopina antitijela……………………..
English: Solution for injection/infusion
Croatian: Otopina za injekciju/infuziju
English: 50 ml
Croatian: Bočica (staklena) 50ml
English: The recommended dose is one tablet once a day and it must be taken with food.
Croatian: Preporučena doza je jedna tableta dnevno, a mora se uzimati s hranom.
English: The full EPAR for Eviplera can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Croatian: Cjeloviti EPAR nalazi se na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: All three active substances are already available in separate medicines in the EU.
Croatian: Sve tri djelatne tvari već su dostupne u EU-u u zasebnim lijekovima.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Eviplera on 28 November 2011.
Croatian: Europska komisija izdala je odobrenje za stavljanje u promet koje za lijek Eviplera vrijedi na prostoru Europske unije od 28. studenoga 2011.
English: It is available as tablets.
Croatian: Dostupan je u obliku tableta.
English: Patients who have HIV and hepatitis B may see a worsening of their liver problems when stopping Eviplera.
Croatian: Bolesnici koji imaju HIV i hepatitis B mogu uočiti pogoršanje svojih problema s jetrom kada prestanu uzimati lijek Eviplera.
English: It also causes fewer side effects in the early stages of treatment and offers the benefit of being taken as one tablet once per day.
Croatian: Također uzrokuje manje nuspojava u ranim stadijima liječenja i nudi pogodnost uzimanja jedne tablete dnevno.
English: What measures are being taken to ensure the safe and effective use of Eviplera?
Croatian: Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Eviplera?
English: Eviplera must not be used with the following medicines as they may lead to reduced blood levels of rilpivirine, and thereby reduce the effectiveness of Eviplera:
Croatian: Eviplera se ne smije koristiti sa sljedećim lijekovima jer oni mogu uzrokovati smanjene razine rilpivirina u krvi i tako umanjiti djelotvornost lijeka Eviplera:
English: Eviplera does not cure HIV-1 infection or AIDS, but it may slow the damage to the immune system and the development of infections and diseases associated with AIDS.
Croatian: Eviplera ne liječi infekciju virusom HIV-1 niti AIDS, ali može usporiti oštećenje imunološkog sustava i razvoj infekcija i bolesti povezanih s AIDS-om.
English: For more information about treatment with Eviplera, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Croatian: Više informacija o terapiji lijekom Eviplera pročitajte u uputi o lijeku (također dio EPAR-a) ili se obratite svojem liječniku ili ljekarniku.
English: If Eviplera is given together with rifabutin, the doctor should prescribe an additional 25 mg of rilpivirine per day during rifabutin treatment.
Croatian: Ako se Eviplera daje zajedno s rifabutinom, liječnik treba propisati dodatnih 25 mg rilpivirina dnevno tijekom liječenja rifabutinom.
English: This is a summary of the European public assessment report (EPAR) for Eviplera.
Croatian: Ovo je sažetak europskoga javnog izvješća o ocjeni dokumentacije (EPAR) za lijek Eviplera.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Eviplera.
Croatian: Objašnjava kako je Odbor za lijekove za humanu uporabu (CHMP) ocijenio lijek da bi donio svoje mišljenje u korist davanja odobrenja za stavljanje lijeka u promet te preporuke o uvjetima za primjenu lijeka Eviplera.
English: By blocking this enzyme, Eviplera reduces the amount of HIV-1 in the blood and keeps it at a low level.
Croatian: Inhibiranjem tog enzima Eviplera smanjuje količinu virusa HIV-1 u krvi i održava je niskom.
English: Other information about Eviplera
Croatian: Ostale informacije o lijeku Eviplera
English: Eviplera emtricitabine / rilpivirine / tenofovir disoproxil
Croatian: Eviplera emtricitabin/rilpivirin/tenofovirdizoproksil
English: Eviplera is a medicine that contains the active substances emtricitabine (200 mg), rilpivirine (25 mg) and tenofovir disoproxil (245 mg).
Croatian: Eviplera je lijek koji sadrži djelatne tvari emtricitabin (200 mg), rilpivirin (25 mg) i tenofovirdizoproksil (245 mg).
English: The company also presented studies showing that the tablet containing all three substances is absorbed in the body in the same way as the separate tablets given concurrently under similar conditions.
Croatian: Proizvođač lijeka također je predočio ispitivanja koja pokazuju da se tableta koja sadrži sve tri tvari apsorbira u tijelu na isti način kao i zasebne tablete koje se daju istovremeno pod sličnim uvjetima.
English: However, the CHMP noted that there was some risk of HIV-1 developing resistance to rilpivirine and that this risk appeared to be lower in patients with a lower viral load.
Croatian: No CHMP je napomenuo da postoji određeni rizik da HIV-1 razvije otpornost na rilpivirin te da se čini da je taj rizik manji u bolesnika s nižim virusnim opterećenjem.
English: If patients need to stop taking one of the active substances or if they need to modify their dose, patients should be switched to separate medicines containing emtricitabine, rilpivirine or tenofovir disoproxil.
Croatian: Ako bolesnici moraju prestati uzimati jednu od djelatnih tvari ili ako moraju promijeniti dozu, potrebno ih je prebaciti na zasebne lijekove koji sadrže emtricitabin, rilpivirin i tenofovirdizoproksil.
English: • systemic dexamethasone (a steroid anti-inflammatory and immunosuppressant medicine) except when used as a single dose treatment;
Croatian: • sistemski deksametazon (steroidni protuupalni lijek i imunosupresant), osim ako se primjenjuje kao terapija jednokratnom dozom;
English: Treatment with Eviplera should be started by a doctor who has experience in the management of HIV infection.
Croatian: Liječenje lijekom Eviplera treba započeti liječnik koji ima iskustva u liječenju infekcija HIV-om.
English: The main measure of effectiveness was based on the reduction in viral load.
Croatian: Glavno mjerilo djelotvornosti temeljilo se na smanjenju virusnog opterećenja.
English: All three active substances block the activity of reverse transcriptase, a viral enzyme that allows HIV-1 to replicate in the cells it has infected.
Croatian: Sve tri djelatne tvari onemogućuju djelovanje reverzne transkriptaze, virusnog enzima koji omogućuje replikaciju virusa HIV-1 u zaraženim stanicama.
English: What is Eviplera?
Croatian: Što je Eviplera?
English: • omeprazole, esomeprazole, lansoprazole, pantoprazole, rabeprazole (proton pump inhibitors for reducing stomach acid);
Croatian: • omeprazol, esomeprazol, lansoprazol, pantoprazol, rabeprazol (inhibitori protonske crpke za smanjivanje lučenja želučane kiseline);
English: It is only used in patients where the virus has not developed resistance to certain anti-HIV medicines called non-nucleoside reverse transcriptase inhibitors (NNRTIs), tenofovir or emtricitabine, and who have HIV levels in the blood (viral load) of no more than 100,000 HIV-1 RNA copies/ml.
Croatian: Koristi se samo u bolesnika kod kojih virus nije razvio otpornost na određene lijekove protiv HIV-a zvane nenukleozidni inhibitori reverzne transkriptaze (NNRTI), tenofovir ili emtricitabin, te kod kojih razina HIV-a u krvi (virusno opterećenje) nije veća od 100 000 HIV-1 RNK kopija/ml.
English: What is the risk associated with Eviplera?
Croatian: Koji su rizici povezani s lijekom Eviplera?
English: Eviplera is used to treat adults infected with human immunodeficiency virus-1 (HIV-1), a virus that causes acquired immune deficiency syndrome (AIDS).
Croatian: Eviplera se koristi u liječenju odraslih osoba zaraženih virusom humane imunodeficijencije-1 (HIV-1) koji uzrokuje sindrom stečene imunodeficijencije (AIDS).
English: The two studies evaluating the effects of switching patients to Eviplera showed that Eviplera was as effective as the previous treatment and maintained the reduction in viral load.
Croatian: Dva ispitivanja u kojima su procijenjeni učinci prelaska bolesnika na lijek Eviplera pokazala su da je lijek Eviplera bio jednako djelotvoran kao i prethodna terapija te da je održano smanjenje virusnog opterećenja.
English: In the first main study involving 690 patients, Eviplera was compared with a similar combination that had efavirenz in place of rilpivirine.
Croatian: U prvom glavnom ispitivanju kojim je bilo obuhvaćeno 690 bolesnika Eviplera je uspoređena sa sličnom kombinacijom koja je sadržavala efavirenc umjesto rilpivirina.
English: The second main study involving 678 patients compared rilpivirine with efavirenz, both being taken with emtricitabine and tenofovir disoproxil or two other nucleotide reverse transcriptase inhibitors.
Croatian: U drugom glavnom ispitivanju kojim je bilo obuhvaćeno 678 bolesnika uspoređen je rilpivirin s efavirencom, pri čemu su oba uzimana s emtricitabinom i tenofovirdizoproksilom ili s druga dva nukleotidna inhibitora reverzne transkiptaze.
English: In the first study in previously untreated patients, 83% of the patients taking the Eviplera combination responded to treatment compared with 84% of the patients taking a combination with efavirenz.
Croatian: U prvom ispitivanju kod bolesnika koji nisu prethodno liječeni, 83 % bolesnika koji su uzimali kombinaciju koja sadrži lijek Eviplera odgovorilo je na terapiju, u usporedbi s 84 % bolesnika koji su uzimali kombinaciju s efavirencom.
English: Eviplera has also been evaluated in 532 patients who were switched from their current HIV treatment to Eviplera.
Croatian: Lijek Eviplera također je ocijenjen u 532 bolesnika koji su prebačeni s postojeće terapije protiv HIV-a na lijek Eviplera.
English: The CHMP concluded that Eviplera was as effective as combinations containing efavirenz.
Croatian: CHMP je zaključio da je lijek Eviplera jednako djelotvoran kao i kombinacije koje sadrže efavirenc.
English: Therefore, the CHMP considered that the benefits of Eviplera outweigh its risks in patients with a low HIV-1 viral load, and recommended that it be granted marketing authorisation for this group of patients.
Croatian: Stoga CHMP smatra da koristi od lijeka Eviplera nadmašuju s njime povezane rizike u bolesnika s niskim opterećenjem virusom HIV-1 te je preporučio izdavanje odobrenja za stavljanje lijeka u promet za tu skupinu bolesnika.
English: What benefit has Eviplera shown during the studies?
Croatian: Koje su koristi lijeka Eviplera dokazane u ispitivanjima?
English: Eviplera contains three active substances: emtricitabine, which is a nucleoside reverse transcriptase inhibitor; rilpivirine, which is a non-nucleoside reverse transcriptase inhibitor (NNRTI); and tenofovir disoproxil, which is a ‘prodrug' of tenofovir, meaning that it is converted into the active substance tenofovir in the body.
Croatian: Eviplera sadrži tri djelatne tvari: emtricitabin, koji je nukleozidni inhibitor reverzne transkriptaze, rilpivirin, koji je nenukleozidni inhibitor reverzne transkriptaze (NNRTI), te tenofovirdizoproksil, koji je „prolijek” tenofovira, što znači da se u tijelu pretvara u djelatnu tvar tenofovir.
English: The main measure of effectiveness was based on the maintained reduction in viral load.
Croatian: Glavno mjerilo djelotvornosti temeljilo se na zadržanom smanjenju virusnog opterećenja.
English: Patient's previous treatment consisted either of two nucleotide reverse transcriptase inhibitors and another HIV medicine called a boosted protease inhibitor, or the medicine Atripla.
Croatian: Prethodna terapija bolesnika sastojala se ili od dva nukleotidna inhibitora reverzne transkriptaze i drugog lijeka protiv HIV-a zvanog pojačani inhibitor proteaze ili od lijeka Atripla.
English: The most common side effects with Eviplera in patients who had not received previous HIV treatment (seen in more than 5 patients in 100) were nausea (feeling sick), dizziness, abnormal dreams, headache, diarrhoea and insomnia.
Croatian: Najčešće nuspojave pri primjeni lijeka Eviplera u bolesnika koji prethodno nisu liječeni od HIV-a (zabilježene u više od 5 na 100 bolesnika) bile su mučnina (osjećaj slabosti), vrtoglavica, abnormalni snovi, glavobolja, proljev i nesanica.
English: Why has Eviplera been approved?
Croatian: Zašto je lijek Eviplera odobren?
English: Eviplera has been studied in two main studies in patients with HIV-1 who had not received HIV treatment before.
Croatian: Lijek Eviplera ispitivan je u dva glavna ispitivanja u bolesnika s virusom HIV-1 koji nisu prethodno primali terapiju protiv HIV-a.
English: • St John's wort (a herbal medicine to treat depression and anxiety).
Croatian: • gospina trava (biljni pripravak za liječenje depresije i tjeskobe).
English: Patients who attained a viral load of less than 50 HIV-1 RNA copies/ml after 48 weeks of treatment were considered to have responded to treatment.
Croatian: Smatralo se da su bolesnici u kojih je nakon 48 tjedana terapije postignuto virusno opterećenje manje od 50 kopija HIV-1 RNK/ml odgovorili na terapiju.
English: In patients who had received previous HIV treatment, the most common side effects (seen in more than 2 patients in 100) were tiredness, diarrhoea, nausea and insomnia.
Croatian: U bolesnika koji su prethodno liječeni protiv HIV-a najčešće nuspojave (zabilježene u više od 2 na 100 bolesnika) bile su umor, proljev, mučnina i nesanica.
English: What is Eviplera used for?
Croatian: Za što se Eviplera koristi?
English: The Eviplera combination compared well with combinations containing efavirenz.
Croatian: Kombinacija koja sadrži lijek Eviplera pokazala se dobrom u usporedbi s kombinacijama koje sadrže efavirenc.
English: In the second study, 87% of the patients in the rilpivirine group (which included patients taking the Eviplera combination) responded to treatment.
Croatian: U drugom ispitivanju 87 % bolesnika u skupini koja je primala rilpivirin (koja je obuhvaćala bolesnike koji su uzimali kombinaciju koja sadrži lijek Eviplera) odgovorilo je na terapiju, u usporedbi s 83 % bolesnika u skupini koja je primala efavirenc.
English: How is Eviplera used?
Croatian: Kako se Eviplera koristi?
English: Rarely, kidney problems may occur in patients taking tenofovir disoproxil.
Croatian: U bolesnika koji uzimaju tenofovirdizoproksil rijetko se mogu pojaviti problemi s bubrezima.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Eviplera have been included in the summary of product characteristics and the package leaflet.
Croatian: U sažetku opisa svojstava lijeka i u uputi o lijeku nalaze se preporuke i mjere opreza za sigurnu i učinkovitu primjenu lijeka Eviplera kojih se zdravstveni radnici i bolesnici trebaju pridržavati.
English: For the full list of side effects and restrictions with Eviplera, see the package leaflet.
Croatian: Potpuni popis nuspojava i ograničenja pri primjeni lijeka Zerit potražite u uputi o lijeku.
English: How has Eviplera been studied?
Croatian: Kako je lijek Eviplera ispitivan?
English: How does Eviplera work?
Croatian: Kako djeluje Eviplera?
English: Onset of immunity: not established.
Croatian: Nastupanje imuniteta: nije ustanovljeno.
English: Respect normal aseptic conditions.
Croatian: Potrebno je pridržavati se uobičajenih aseptičkih uvjeta.
English: Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu/.
Croatian: Detaljne informacije o ovom veterinarsko-medicinskom proizvodu su dostupne na web stranici Europske agencije za lijekove (http://www.ema.europa.eu/).
English: CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER OF DOSES
Croatian: SADRŽAJPO TEŽINI, VOLUMENU ILI BROJU DOZA
English: ATCvet code: QI02AB.
Croatian: ATCvet kod: QI02AB
English: Date of last renewal: 31/07/2015
Croatian: Datum zadnjeg produženja: 31/07/2015
English: There are no benefits of the vaccine (as described in the indications for cattle), when used in infected and/or pregnant cows.
Croatian: Nema koristi od vakcine (kao što je opisano u indikacijama za goveda), ukoliko se koristi kod zaraženih i/ili gravidnih krava.
English: Vaccination of animals already infected at the time of vaccination will have no adverse effect.
Croatian: Vakcinacija životinja već zaraženih u trenutku vakcinacije neće imati negativnog učinka.
English: Date of first authorisation: 30/09/2010.
Croatian: Datum prvog odobrenja: 30/09/2010
English: Primary vaccination:
Croatian: Primarna vakcinacija:
English: Since stress could contribute to this adverse reaction, appropriate precautions should be taken to reduce stress as much as possible during the administration of the product.
Croatian: Budući da stres može doprinijeti toj neželjenoj reakciji potrebno je poduzeti odgovarajuće mjere opreza kako bi smanjili stres pri vakcinaciji koliko god je to moguće.
English: Suspension for injection.
Croatian: OBLIK Suspenzija za injekcije.
English: Each ml contains:
Croatian: Svaki ml suspenzije sadržava:
English: Under normal conditions the timing of vaccination should be planned so that the primary course is completed by 3 weeks before artificial insemination or mating.
Croatian: Pri normalnim okolnostima vrijeme vakcinacije treba planirati tako da primarna vakcinacija bude dovršena najkasnije 3 tjedna prije umjetnog osjemenjivanja ili parenja.
English: Sodium chloride Disodium hydrogen phosphate Potassium dihydrogen phosphate Water for injections
Croatian: Natrijev klorid Dinatrijev hidrogen fosfat Kalij dihidrogen fosfat Voda za injekcije
English: Whitish, opalescent, homogeneous suspension.
Croatian: Blijeda, opalescentna, homogena suspenzija.
English: Administer the vaccine as follows: Cattle: 4 ml in the neck region.
Croatian: Vakcinu valja davati na sljedeći način: Goveda: 4 ml u području vrata.
English: Inactivated Coxiella burnetii, strain Nine Mile
Croatian: Inaktivirana Coxiella burnetii, soj Nine Mile
English: 4.7 Use during pregnancy, lactation or lay
Croatian: 4.7 Primjena tijekom graviditeta, laktacije ili nesenja Laktacija:
English: HUNGARY
Croatian: MAĐARSKA
English: Cattle and goats
Croatian: Goveda i koze
English: The excipients listed in section 6.1 of the SPC are either allowed substances for which table 1 of the annex to Commission Regulation (EU) No 37/2010 indicates that no MRLs are required or considered as not falling within the scope of Regulation (EC) No 470/2009 when used as in this veterinary medicinal product.
Croatian: Pomoćne tvari (uključujući adjuvanse) navedene u dijelu 6.1 SPC su ili dozvoljene tvari za koje je u tablici 1, Dodatka Uredbe Komisije (EU) br. 37/2010 naznačeno da određivanje MRL nije nužno, ili se smatra da se na njih ne primjenjuju odredbe Uredbe (EZ) br. 470/2009 kada se primjenjuju u tim veterinarsko medicinskim proizvodima.
English: It is advisable to vaccinate all the animals in the herd at the same time.
Croatian: Preporuča se vakcinirati sve životinje u stadu u isto vrijeme.
English: In the case that it is decided to vaccinate the whole herd, it is advisable to vaccinate the male animals at the same time.
Croatian: U slučaju vakcinacije cijelog stada poželjno je istovremeno vakcinirati i muške životinje.
English: CEVA Sante Animale 10 avenue de la Ballastiere 33500 Libourne FRANCE
Croatian: CEVA Sante Animale 10 avenue de la Ballastiere 33500 Libourne FRANCUSKA
English: Duration of immunity: one year after completion of the primary vaccination course.
Croatian: Trajanje imuniteta: godinu dana po završetku primarnog vakcinalnog ciklusa.
English: The active substance being a principle of biological origin intended to produce active immunity is not within the scope of Regulation (EC) No 470/2009.
Croatian: Djelatna tvar koja se sastoji od tvari biološkog podrijetla, namijenjene je za poticanje aktivne imunosti na koju se ne primjenjuju odredbe Uredbe (EK) br. 470/2009.
English: Cattle from 3 months of age:
Croatian: Goveda starija od 3 mjeseca:
English: Incompatibilities: Do not mix with any other veterinary medicinal product.
Croatian: Inkompatibilnost: Ne miješati s bilo kojim drugim veterinarsko medicinskim proizvodom.
English: Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements.
Croatian: Bilo koji neupotrebljeni veterinarsko-medicinski proizvod ili otpadni materijali dobiven primjenom tih veterinarsko-medicinskih proizvoda treba se odlagati u skladu s lokalnim propisima.
English: According to Article 71 of Directive 2001/82/EC of the European Parliament and of the Council as amended, a Member State may, in accordance with its national legislation, prohibit the manufacture, import, possession, sale, supply and/or use of immunological veterinary medicinal products on the whole or part of its territory if it is established that:
Croatian: Sukladno članku 71. Direktive 2001/82/EZ i Europskog Parlamenta i Vijeća koja je dopunjena, država članica može zabraniti proizvodnju, uvoz, prodaju, opskrbu i/ili primjenu veterinarsko medicinskog proizvoda na cijelom ili na dijelu svog teritorija ako je utvrđeno da:
English: Goats from 3 months of age:
Croatian: Koze starije od 3 mjeseca:
English: The biological significance of the levels of reduction shown in shedding in cattle and goats is not known.
Croatian: Biološki značaj razine smanjenja širenja bolesti u goveda i koza nije poznat.
English: Lactation: The vaccine can be used during lactation.
Croatian: Laktacija: Vakcina se može koristiti tijekom laktacije.
English: Goats: 2 ml in the neck region.
Croatian: Koze: 2 ml u području vrata.
English: > 72 QF Units* *QF (Q fever) Unit: relative potency of phase I antigen measured by ELISA in comparison with a reference item.
Croatian: ≥72 QF jedinica* *QF (Q groznica) jedinica: relativna potencija faze I antigena izmjerenog ELISA testom u usporedbi s referentnom vrijednošću Pomoćne tvari:
English: No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product.
Croatian: Nema dostupnih podataka o neškodljivosti i učinkovitosti ove vakcine kada se koristiti s bilo kojim drugim veterinarsko medicinskim proizvodom.